SCHEMBL23850890

SCHEMBL23850890

CS(=O)(=O)c1ccc(N2CCC(F)CC2)c([N+](=O)[O-])c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
ALDH1A1 P00352 5/20 0.58
LMNA P02545 5/20 0.57
GAA P10253 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
MAPK1 P28482 2/20 0.57
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.50
RECQL P46063 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
CTPS1 P17812 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
HTT P42858 1/20 0.48
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587902 0.86 ALDH1A1 (0.55) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23850661 0.86 ALDH1A1 (0.55) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23850665 0.86 ALDH1A1 (0.55) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL9980456 0.86 MAPT (0.77) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23850918 0.85 LMNA (0.78) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL31587392 0.85 LMNA (0.78) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23851419 0.83 LMNA (0.56) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL20524585 0.79 GPR6 (0.59) MAPTLMNAGAASMN1; SMN2MAPK1
SCHEMBL23850389 0.79 RAB9A (0.50) MAPTALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL23850205 0.79 LMNA (0.65) MAPTALDH1A1LMNAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed
CN-113056305-A Compound (I) 格雷沃尔夫治疗有限公司 2021-06-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 MAPT 4705/4885ALDH1A1 2613/4885LMNA 2596/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR MAPT 302/4885ALDH1A1 276/4885LMNA 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.